Prevention · Screening · Early detection

Cervical Cancer Screening and HPV Testing

Cervical screening can find infection-related risk and precancer. Treating precancer can prevent invasive cancer.

Chapter 9 of 16

9 of 16
Choose a chapter

Key facts

  • Persistent high-risk HPV is the main cause of cervical cancer.
  • A positive HPV test is not a cancer diagnosis.
  • Vaccinated people with a cervix still need appropriate screening.

Recommendations at a glance

These are guideline comparisons, not a personalised prescription. Symptoms and high-risk history take priority over routine screening schedules.

Eligibility, timing and limitations
Guideline / groupAge or eligibilityTest / intervalImportant limitation
USPSTF 2018 final21–29; 30–6521–29: Pap 3 years; 30–65: Pap 3 or HPV/cotest 5 yearsUpdate in progress; high-risk follow-up differs
WHO general populationFrom 30HPV DNA generally every 5–10 yearsUse a validated local pathway
WHO: living with HIVFrom 25Generally every 3–5 yearsDifferent follow-up after abnormal results
ACS average risk25 through at least 65Clinician HPV 5 years; approved self-collection 3 yearsStopping requires adequate negative history
India 2016 framework30–65VIA every 5 yearsConfirm current state service and test

Choose the right next step

  1. New or concerning symptoms? Arrange diagnostic assessment. Severe bleeding, breathlessness or new neurological weakness needs urgent care.
  2. No symptoms, but previous cancer, precancer or increased inherited risk? Ask for an individual surveillance plan; average-risk intervals may not apply.
  3. No such history? Use this chapter to discuss prevention and, where appropriate, age- and test-specific screening. Lifestyle exposures alone do not establish eligibility for every test.
  4. After testing: Collect the result, complete any referral, and record the next review date. A normal screen does not explain a later symptom.

What the tests measure

Primary HPV testing detects high-risk viral types. A Pap test examines cervical cells for changes; cotesting combines both. Visual inspection with acetic acid (VIA) allows trained staff to inspect the cervix after dilute acetic acid. Test quality, follow-up pathways and eligibility matter; these methods should not be treated as interchangeable at the same interval.

WHO and Indian approaches

WHO’s screening framework starts high-performance testing at 30 for the general population, typically every 5–10 years for HPV DNA testing. For women living with HIV, WHO starts at 25 with intervals generally 3–5 years. India’s 2016 common-cancer framework uses VIA at 30–65 every five years. Updated local services may use HPV testing; confirm which programme and method apply.

ACS comparison and self-collection

ACS 2025 starts average-risk screening at 25. Clinician-collected primary HPV testing every five years is preferred; approved self-collected HPV testing is every three years, cotesting every five and Pap alone every three when other options are unavailable. The self-collection advice is tied to approved devices and laboratory pathways in the United States, not permission to use any home kit in India.

USPSTF differs from ACS and WHO

The accessible USPSTF final recommendation is dated 2018, with an update in progress: cytology every three years at 21–29; at 30–65, cytology every three years, primary high-risk HPV every five years, or cotesting every five years. ACS starts at 25 and WHO population guidance at 30 (25 with HIV). These ages and test pathways should not be mixed. Previous high-grade precancer, immune suppression or abnormal results require a separate follow-up plan.

A simple screening pathway

No symptoms → confirm cervix, age, history and immune status → choose a locally validated screening test → obtain the result → follow the test-specific pathway. A negative result usually leads to the planned interval. A positive result may need HPV genotyping, cytology, colposcopy or another protocol-directed step. Selected programmes allow screen-and-treat after eligibility assessment; this is not self-treatment or a cancer diagnosis.

Abnormal results and treatment

Colposcopy is a closer examination of the cervix, often with biopsy. Precancer can be treated by ablation or excision in suitable circumstances. Suspected invasive cancer requires diagnostic referral rather than routine ablative treatment. Follow-up after treatment is essential and differs from routine screening. Pregnancy, HIV, transplant medicines and previous high-grade lesions change management.

When to stop and when to investigate symptoms

Stopping around 65 under ACS requires adequate documented negative prior tests and no high-risk reason to continue; unknown history is not proof of eligibility to stop. A total hysterectomy for benign disease may remove the need if the cervix was removed and relevant precancer history is absent. Bleeding after intercourse, between periods or after menopause needs diagnostic assessment regardless of screening or vaccination.

Test limitations and older age

HPV-based screening is generally more sensitive for high-grade precancer than cytology, but more positives can lead to additional assessment. VIA is examiner-dependent and becomes less reliable after menopause. A positive HPV result is not proof of cancer. Before stopping under ACS, review documented recent negative results: two sequential negative HPV-based tests at the appropriate interval, or three negative Pap tests, with screening continued through at least 65. Unknown history and previous precancer need clinician review; do not stop on age alone.

Practical steps

  • Keep copies of HPV, Pap, biopsy and treatment reports.
  • Check whether the cervix remains after hysterectomy.
  • Ask how an abnormal result will be followed up.
  • Continue screening after vaccination as recommended.

Myth and fact

A positive HPV test proves recent infidelity.

False. HPV can persist or become detectable long after acquisition; the test cannot establish when infection occurred.

Frequently asked questions

Does a positive HPV test mean I have cancer?

No. It identifies an infection requiring appropriate triage or follow-up.

Can I stop at 65 if I have never been screened?

Do not assume so. A clinician should review your history and arrange appropriate testing.

Continue learning

Sources and guideline context